share_log

Panbela Therapeutics | UPLOAD: Others

Panbela Therapeutics | UPLOAD: Others

Panbela Therapeutics | UPLOAD:其他
美股sec公告 ·  04/02 12:45
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on March 29, 2024, will not undergo review. The SEC's communication, dated April 2, 2024, was addressed to Jennifer Simpson, CEO of Panbela Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Jessica Dickerson from the Division of Corporation Finance Office of Life Sciences.
Panbela Therapeutics, Inc., a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on March 29, 2024, will not undergo review. The SEC's communication, dated April 2, 2024, was addressed to Jennifer Simpson, CEO of Panbela Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Jessica Dickerson from the Division of Corporation Finance Office of Life Sciences.
美國證券交易委員會(SEC)已告知生物製藥公司Panbela Therapeutics, Inc.,其於2024年3月29日提交的S-1表格的註冊聲明將不接受審查。美國證券交易委員會於2024年4月2日發給了Panbela Therapeutics首席執行官詹妮弗·辛普森的來文。美國證券交易委員會的信中引用了第460和461條,這兩條規則與加快註冊程序的請求有關。此外,美國證券交易委員會提醒該公司及其管理層,無論美國證券交易委員會的審查程度如何,他們都對披露的準確性和充分性負責。爲了進一步調查,美國證券交易委員會提供了生命科學公司財務部傑西卡·迪克森的聯繫信息。
美國證券交易委員會(SEC)已告知生物製藥公司Panbela Therapeutics, Inc.,其於2024年3月29日提交的S-1表格的註冊聲明將不接受審查。美國證券交易委員會於2024年4月2日發給了Panbela Therapeutics首席執行官詹妮弗·辛普森的來文。美國證券交易委員會的信中引用了第460和461條,這兩條規則與加快註冊程序的請求有關。此外,美國證券交易委員會提醒該公司及其管理層,無論美國證券交易委員會的審查程度如何,他們都對披露的準確性和充分性負責。爲了進一步調查,美國證券交易委員會提供了生命科學公司財務部傑西卡·迪克森的聯繫信息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息